Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 146

1.

TIV Vaccination Modulates Host Responses to Influenza Virus Infection that Correlate with Protection against Bacterial Superinfection.

Choi A, Christopoulou I, Saelens X, García-Sastre A, Schotsaert M.

Vaccines (Basel). 2019 Sep 12;7(3). pii: E113. doi: 10.3390/vaccines7030113.

2.

Single-Domain Antibodies and Their Formatting to Combat Viral Infections.

De Vlieger D, Ballegeer M, Rossey I, Schepens B, Saelens X.

Antibodies (Basel). 2018 Dec 20;8(1). pii: E1. doi: 10.3390/antib8010001. Review.

3.

Identification of peptide domains involved in the subcellular localization of the feline coronavirus 3b protein.

Acar DD, Stroobants VJE, Favoreel H, Saelens X, Nauwynck HJ.

J Gen Virol. 2019 Oct;100(10):1417-1430. doi: 10.1099/jgv.0.001321. Epub 2019 Aug 30.

PMID:
31483243
4.

Delivery of Mixed-Lineage Kinase Domain-Like Protein by Vapor Nanobubble Photoporation Induces Necroptotic-Like Cell Death in Tumor Cells.

Van Hoecke L, Raes L, Stremersch S, Brans T, Fraire JC, Roelandt R, Declercq W, Vandenabeele P, Raemdonck K, Braeckmans K, Saelens X.

Int J Mol Sci. 2019 Aug 30;20(17). pii: E4254. doi: 10.3390/ijms20174254.

5.

Intranodal administration of mRNA encoding nucleoprotein provides cross-strain immunity against influenza in mice.

Joe PT, Christopoulou I, van Hoecke L, Schepens B, Ysenbaert T, Heirman C, Thielemans K, Saelens X, Aerts JL.

J Transl Med. 2019 Jul 25;17(1):242. doi: 10.1186/s12967-019-1991-3.

6.

New antibody-based prevention and treatment options for influenza.

Sedeyn K, Saelens X.

Antiviral Res. 2019 Oct;170:104562. doi: 10.1016/j.antiviral.2019.104562. Epub 2019 Jul 16. Review.

PMID:
31323236
7.

Therapeutic anti-tumor immunity directed against neo-epitopes by intratumor delivery of mRNA encoding MLKL.

Van Hoecke L, Saelens X.

Cell Stress. 2018 Oct 2;2(10):279-281. doi: 10.15698/cst2018.10.160.

8.

Mx1 in Hematopoietic Cells Protects against Thogoto Virus Infection.

Spitaels J, Van Hoecke L, Roose K, Kochs G, Saelens X.

J Virol. 2019 Jul 17;93(15). pii: e00193-19. doi: 10.1128/JVI.00193-19. Print 2019 Aug 1.

PMID:
31092574
9.

Super-resolution microscopy reveals significant impact of M2e-specific monoclonal antibodies on influenza A virus filament formation at the host cell surface.

Kolpe A, Arista-Romero M, Schepens B, Pujals S, Saelens X, Albertazzi L.

Sci Rep. 2019 Mar 14;9(1):4450. doi: 10.1038/s41598-019-41023-5.

10.

A two-amino acid mutation in murine IgA enables downstream processing and purification on staphylococcal superantigen-like protein 7.

Bakshi S, Depicker A, Schepens B, Saelens X, Juarez P.

J Biotechnol. 2019 Mar 20;294:26-29. doi: 10.1016/j.jbiotec.2019.01.020. Epub 2019 Feb 13.

PMID:
30771443
11.

Vaccination with influenza hemagglutinin-loaded ceramic nanoporous microneedle arrays induces protective immune responses.

Schepens B, Vos PJ, Saelens X, van der Maaden K.

Eur J Pharm Biopharm. 2019 Mar;136:259-266. doi: 10.1016/j.ejpb.2019.02.002. Epub 2019 Feb 5.

PMID:
30731115
12.

The Role of Matrix Protein 2 Ectodomain in the Development of Universal Influenza Vaccines.

Saelens X.

J Infect Dis. 2019 Apr 8;219(Supplement_1):S68-S74. doi: 10.1093/infdis/jiz003.

13.

Broadened immunity against influenza by vaccination with computationally designed influenza virus N1 neuraminidase constructs.

Job ER, Ysenbaert T, Smet A, Christopoulou I, Strugnell T, Oloo EO, Oomen RP, Kleanthous H, Vogel TU, Saelens X.

NPJ Vaccines. 2018 Nov 29;3:55. doi: 10.1038/s41541-018-0093-1. eCollection 2018.

14.

Author Correction: A reassortant H9N2 influenza virus containing 2009 pandemic H1N1 internal-protein genes acquired enhanced pig-to-pig transmission after serial passages in swine.

Mancera Gracia JC, Van den Hoecke S, Richt JA, Ma W, Saelens X, Van Reeth K.

Sci Rep. 2018 Nov 16;8(1):17222. doi: 10.1038/s41598-018-35446-9.

15.

Species Specificity of Type III Interferon Activity and Development of a Sensitive Luciferase-Based Bioassay for Quantitation of Mouse Interferon-λ.

Jacobs S, Wavreil F, Schepens B, Gad HH, Hartmann R, Rocha-Pereira J, Neyts J, Saelens X, Michiels T.

J Interferon Cytokine Res. 2018 Nov;38(11):469-479. doi: 10.1089/jir.2018.0066. Epub 2018 Oct 18.

16.

Porous Nanoparticles With Self-Adjuvanting M2e-Fusion Protein and Recombinant Hemagglutinin Provide Strong and Broadly Protective Immunity Against Influenza Virus Infections.

Bernasconi V, Bernocchi B, Ye L, Lê MQ, Omokanye A, Carpentier R, Schön K, Saelens X, Staeheli P, Betbeder D, Lycke N.

Front Immunol. 2018 Sep 12;9:2060. doi: 10.3389/fimmu.2018.02060. eCollection 2018.

17.

Passively transferred M2e-specific monoclonal antibody reduces influenza A virus transmission in mice.

Kolpe A, Schepens B, Ye L, Staeheli P, Saelens X.

Antiviral Res. 2018 Oct;158:244-254. doi: 10.1016/j.antiviral.2018.08.017. Epub 2018 Sep 1.

PMID:
30179634
18.

Treatment with mRNA coding for the necroptosis mediator MLKL induces antitumor immunity directed against neo-epitopes.

Van Hoecke L, Van Lint S, Roose K, Van Parys A, Vandenabeele P, Grooten J, Tavernier J, De Koker S, Saelens X.

Nat Commun. 2018 Aug 24;9(1):3417. doi: 10.1038/s41467-018-05979-8.

19.

Surfactant protein B (SP-B) enhances the cellular siRNA delivery of proteolipid coated nanogels for inhalation therapy.

Merckx P, De Backer L, Van Hoecke L, Guagliardo R, Echaide M, Baatsen P, Olmeda B, Saelens X, Pérez-Gil J, De Smedt SC, Raemdonck K.

Acta Biomater. 2018 Sep 15;78:236-246. doi: 10.1016/j.actbio.2018.08.012. Epub 2018 Aug 15.

PMID:
30118853
20.

Removal of the N-Glycosylation Sequon at Position N116 Located in p27 of the Respiratory Syncytial Virus Fusion Protein Elicits Enhanced Antibody Responses after DNA Immunization.

Leemans A, Boeren M, Van der Gucht W, Pintelon I, Roose K, Schepens B, Saelens X, Bailey D, Martinet W, Caljon G, Maes L, Cos P, Delputte P.

Viruses. 2018 Aug 14;10(8). pii: E426. doi: 10.3390/v10080426.

21.

Neutralization of Junín virus by single domain antibodies targeted against the nucleoprotein.

Linero F, Sepúlveda C, Christopoulou I, Hulpiau P, Scolaro L, Saelens X.

Sci Rep. 2018 Jul 30;8(1):11451. doi: 10.1038/s41598-018-29508-1.

22.

Vaccine options for influenza: thinking small.

Schepens B, De Vlieger D, Saelens X.

Curr Opin Immunol. 2018 Aug;53:22-29. doi: 10.1016/j.coi.2018.03.024. Epub 2018 Apr 7. Review.

PMID:
29631195
23.

A Respiratory Syncytial Virus Vaccine Based on the Small Hydrophobic Protein Ectodomain Presented With a Novel Lipid-Based Formulation Is Highly Immunogenic and Safe in Adults: A First-in-Humans Study.

Langley JM, MacDonald LD, Weir GM, MacKinnon-Cameron D, Ye L, McNeil S, Schepens B, Saelens X, Stanford MM, Halperin SA.

J Infect Dis. 2018 Jul 2;218(3):378-387. doi: 10.1093/infdis/jiy177.

24.

Potent anti-viral vaccine adjuvant based on pH-degradable nanogels with covalently linked small molecule imidazoquinoline TLR7/8 agonist.

Nuhn L, Van Hoecke L, Deswarte K, Schepens B, Li Y, Lambrecht BN, De Koker S, David SA, Saelens X, De Geest BG.

Biomaterials. 2018 Sep;178:643-651. doi: 10.1016/j.biomaterials.2018.03.026. Epub 2018 Mar 16.

PMID:
29573820
25.

Corrigendum: Potent single-domain antibodies that arrest respiratory syncytial virus fusion protein in its prefusion state.

Rossey I, Gilman MSA, Kabeche SC, Sedeyn K, Wrapp D, Kanekiyo M, Chen M, Mas V, Spitaels J, Melero JA, Graham BS, Schepens B, McLellan JS, Saelens X.

Nat Commun. 2017 Nov 29;8:16165. doi: 10.1038/ncomms16165.

26.

Transiently Thermoresponsive Acetal Polymers for Safe and Effective Administration of Amphotericin B as a Vaccine Adjuvant.

Van Herck S, Van Hoecke L, Louage B, Lybaert L, De Coen R, Kasmi S, Esser-Kahn AP, David SA, Nuhn L, Schepens B, Saelens X, De Geest BG.

Bioconjug Chem. 2018 Mar 21;29(3):748-760. doi: 10.1021/acs.bioconjchem.7b00641. Epub 2017 Dec 13.

PMID:
29172458
27.

Antibodies Directed toward Neuraminidase N1 Control Disease in a Mouse Model of Influenza.

Job ER, Schotsaert M, Ibañez LI, Smet A, Ysenbaert T, Roose K, Dai M, de Haan CAM, Kleanthous H, Vogel TU, Saelens X.

J Virol. 2018 Jan 30;92(4). pii: e01584-17. doi: 10.1128/JVI.01584-17. Print 2018 Feb 15.

28.

Clinical Potential of Prefusion RSV F-specific Antibodies.

Rossey I, McLellan JS, Saelens X, Schepens B.

Trends Microbiol. 2018 Mar;26(3):209-219. doi: 10.1016/j.tim.2017.09.009. Epub 2017 Oct 17. Review.

PMID:
29054341
29.

Oral delivery of Escherichia coli persistently infected with M2e-displaying bacteriophages partially protects against influenza A virus.

Deng L, Roose K, Job ER, De Rycke R, Van Hamme E, Gonçalves A, Parthoens E, Cicchelero L, Sanders N, Fiers W, Saelens X.

J Control Release. 2017 Oct 28;264:55-65. doi: 10.1016/j.jconrel.2017.08.020. Epub 2017 Aug 24.

PMID:
28842314
30.

Inflammatory monocytes regulate Th1 oriented immunity to CpG adjuvanted protein vaccines through production of IL-12.

De Koker S, Van Hoecke L, De Beuckelaer A, Roose K, Deswarte K, Willart MA, Bogaert P, Naessens T, De Geest BG, Saelens X, Lambrecht BN, Grooten J.

Sci Rep. 2017 Jul 20;7(1):5986. doi: 10.1038/s41598-017-06236-6.

31.

Bronchoalveolar Lavage of Murine Lungs to Analyze Inflammatory Cell Infiltration.

Van Hoecke L, Job ER, Saelens X, Roose K.

J Vis Exp. 2017 May 4;(123). doi: 10.3791/55398.

32.

A reassortant H9N2 influenza virus containing 2009 pandemic H1N1 internal-protein genes acquired enhanced pig-to-pig transmission after serial passages in swine.

Mancera Gracia JC, Van den Hoecke S, Richt JA, Ma W, Saelens X, Van Reeth K.

Sci Rep. 2017 May 2;7(1):1323. doi: 10.1038/s41598-017-01512-x. Erratum in: Sci Rep. 2018 Nov 16;8(1):17222.

33.

Effect of serial pig passages on the adaptation of an avian H9N2 influenza virus to swine.

Mancera Gracia JC, Van den Hoecke S, Saelens X, Van Reeth K.

PLoS One. 2017 Apr 6;12(4):e0175267. doi: 10.1371/journal.pone.0175267. eCollection 2017.

34.

M2e-tetramer-specific memory CD4 T cells are broadly protective against influenza infection.

Eliasson DG, Omokanye A, Schön K, Wenzel UA, Bernasconi V, Bemark M, Kolpe A, El Bakkouri K, Ysenbaert T, Deng L, Fiers W, Saelens X, Lycke N.

Mucosal Immunol. 2018 Jan;11(1):273-289. doi: 10.1038/mi.2017.14. Epub 2017 Mar 1.

PMID:
28295019
35.

Bispecific T cell engaging antibody constructs targeting a universally conserved part of the viral M2 ectodomain cure and prevent influenza A virus infection.

Pendzialek J, Roose K, Smet A, Schepens B, Kufer P, Raum T, Baeuerle PA, Muenz M, Saelens X, Fiers W.

Antiviral Res. 2017 May;141:155-164. doi: 10.1016/j.antiviral.2017.02.016. Epub 2017 Mar 1.

PMID:
28257797
36.

Potent single-domain antibodies that arrest respiratory syncytial virus fusion protein in its prefusion state.

Rossey I, Gilman MS, Kabeche SC, Sedeyn K, Wrapp D, Kanekiyo M, Chen M, Mas V, Spitaels J, Melero JA, Graham BS, Schepens B, McLellan JS, Saelens X.

Nat Commun. 2017 Feb 13;8:14158. doi: 10.1038/ncomms14158. Erratum in: Nat Commun. 2017 Nov 29;8:16165.

37.

IgG3 Snitcher of RSV Infections in the Very Young.

Schepens B, Saelens X.

EBioMedicine. 2017 Feb;16:10-11. doi: 10.1016/j.ebiom.2017.01.039. Epub 2017 Jan 30. No abstract available.

38.

Hierarchical and Redundant Roles of Activating FcγRs in Protection against Influenza Disease by M2e-Specific IgG1 and IgG2a Antibodies.

Van den Hoecke S, Ehrhardt K, Kolpe A, El Bakkouri K, Deng L, Grootaert H, Schoonooghe S, Smet A, Bentahir M, Roose K, Schotsaert M, Schepens B, Callewaert N, Nimmerjahn F, Staeheli P, Hengel H, Saelens X.

J Virol. 2017 Mar 13;91(7). pii: e02500-16. doi: 10.1128/JVI.02500-16. Print 2017 Apr 1.

39.

Chemical-controlled Activation of Antiviral Myxovirus Resistance Protein 1.

Verhelst J, Van Hoecke L, Spitaels J, De Vlieger D, Kolpe A, Saelens X.

J Biol Chem. 2017 Feb 10;292(6):2226-2236. doi: 10.1074/jbc.M116.748806. Epub 2016 Dec 23.

40.

Regulation of kynurenine biosynthesis during influenza virus infection.

Gaelings L, Söderholm S, Bugai A, Fu Y, Nandania J, Schepens B, Lorey MB, Tynell J, Vande Ginste L, Le Goffic R, Miller MS, Kuisma M, Marjomäki V, De Brabander J, Matikainen S, Nyman TA, Bamford DH, Saelens X, Julkunen I, Paavilainen H, Hukkanen V, Velagapudi V, Kainov DE.

FEBS J. 2017 Jan;284(2):222-236. doi: 10.1111/febs.13966. Epub 2016 Dec 14.

41.

Increased Protein Degradation Improves Influenza Virus Nucleoprotein-Specific CD8+ T Cell Activation In Vitro but Not in C57BL/6 Mice.

Altenburg AF, van de Sandt CE, van Trierum SE, De Gruyter HLM, van Run PRWA, Fouchier RAM, Roose K, Saelens X, Volz A, Sutter G, de Vries RD, Rimmelzwaan GF.

J Virol. 2016 Oct 28;90(22):10209-10219. doi: 10.1128/JVI.01633-16. Print 2016 Nov 15.

42.

Influenza and Memory T Cells: How to Awake the Force.

Spitaels J, Roose K, Saelens X.

Vaccines (Basel). 2016 Oct 13;4(4). pii: E33. Review.

43.

M2-based influenza vaccines: recent advances and clinical potential.

Kolpe A, Schepens B, Fiers W, Saelens X.

Expert Rev Vaccines. 2017 Feb;16(2):123-136. doi: 10.1080/14760584.2017.1240041. Epub 2016 Oct 5. Review.

PMID:
27653543
44.

Type I Interferons Interfere with the Capacity of mRNA Lipoplex Vaccines to Elicit Cytolytic T Cell Responses.

De Beuckelaer A, Pollard C, Van Lint S, Roose K, Van Hoecke L, Naessens T, Udhayakumar VK, Smet M, Sanders N, Lienenklaus S, Saelens X, Weiss S, Vanham G, Grooten J, De Koker S.

Mol Ther. 2016 Nov;24(11):2012-2020. doi: 10.1038/mt.2016.161. Epub 2016 Aug 10.

45.

Phosphoproteomics to Characterize Host Response During Influenza A Virus Infection of Human Macrophages.

Söderholm S, Kainov DE, Öhman T, Denisova OV, Schepens B, Kulesskiy E, Imanishi SY, Corthals G, Hintsanen P, Aittokallio T, Saelens X, Matikainen S, Nyman TA.

Mol Cell Proteomics. 2016 Oct;15(10):3203-3219. Epub 2016 Aug 2.

46.

Illumina MiSeq sequencing disfavours a sequence motif in the GFP reporter gene.

Van den Hoecke S, Verhelst J, Saelens X.

Sci Rep. 2016 May 19;6:26314. doi: 10.1038/srep26314.

47.

One Against All: A Broadly Influenza Neutralizing Man-made Monoclonal Antibody Passes Phase I.

Saelens X.

EBioMedicine. 2016 Feb 26;5:16-7. doi: 10.1016/j.ebiom.2016.02.036. eCollection 2016 Mar. No abstract available.

48.

Production and Purification of Recombinant Filamentous Bacteriophages Displaying Immunogenic Heterologous Epitopes.

Deng L, Linero F, Saelens X.

Methods Mol Biol. 2016;1404:483-95. doi: 10.1007/978-1-4939-3389-1_31.

PMID:
27076317
49.

Long-Lasting Cross-Protection Against Influenza A by Neuraminidase and M2e-based immunization strategies.

Schotsaert M, Ysenbaert T, Smet A, Schepens B, Vanderschaeghe D, Stegalkina S, Vogel TU, Callewaert N, Fiers W, Saelens X.

Sci Rep. 2016 Apr 13;6:24402. doi: 10.1038/srep24402.

50.

Influenza-binding sialylated polymer coated gold nanoparticles prepared via RAFT polymerization and reductive amination.

Zhang Z, Schepens B, Nuhn L, Saelens X, Schotsaert M, Callewaert N, De Rycke R, Zhang Q, Moins S, Benali S, Mespouille L, Hoogenboom R, De Geest BG.

Chem Commun (Camb). 2016 Feb 25;52(16):3352-5. doi: 10.1039/c6cc00501b.

PMID:
26823186

Supplemental Content

Loading ...
Support Center